BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GDC-0973: Interim Phase Ib data

Interim data from 27 patients in an ongoing, open-label, dose-escalation, U.S. Phase Ib trial showed that once-daily oral GDC-0973 plus GDC-0941 for 21 days followed by 7 days off treatment produced 3 cases of stable disease for >6 months. Additionally, 2 patients with...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >